Designing, Validation, and Feasibility of Integrated Approach of Heartfulness Meditation and Yoga Protocol (IAHFNM & YP) for Hypertensive Participants

IF 3.4 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Therapeutics Pub Date : 2024-07-04 DOI:10.1155/2024/9289232

Pooja S. Singh, Veronique Nicolai, Yogesh Patil, Neelam Yeram, Bhusan Bhukte, Kapil Thakur, Mitesh Thakker, Haresh Mehta, Mansee K. Thakur

{"title":"Designing, Validation, and Feasibility of Integrated Approach of Heartfulness Meditation and Yoga Protocol (IAHFNM & YP) for Hypertensive Participants","authors":"Pooja S. Singh, Veronique Nicolai, Yogesh Patil, Neelam Yeram, Bhusan Bhukte, Kapil Thakur, Mitesh Thakker, Haresh Mehta, Mansee K. Thakur","doi":"10.1155/2024/9289232","DOIUrl":null,"url":null,"abstract":"The module was designed and developed at Heartfulness Institute, Kanha Shanti Vanam, Hyderabad. The Department of Medicine, MGM Medical College & Hospital, MGMIHS, Navi Mumbai, carried out the validation and subsequently pilot-tested on volunteers. Forty experts were selected to validate the contents of IAHFNM & YP which was designed after a thorough review of meditation and yoga literature. A total of 23 items were included, and each item was rated as essential or not essential by the experts, based on which the content validity ratio (CVR), Item-Level Content Validity Index (I-CVI), and Scale-Level Content Validity Index Average (S-CVI/Ave) were calculated. Reliability analysis and a pilot study for the feasibility of IAHFNM & YP for hypertensive patients were also done. All 23 practices exhibited significant CVR (≥ 0.29), I-CVI (> 0.79), and S-CVI/Ave (> 0.9); thus, the tool was found to have valid contents. Cronbach’s alpha value for the tool was 0.95 which was highly reliable. Feasibility analysis in hypertensive participants showed that the tool is reliable and implementable. The IAHFNM & YP tool designed for hypertensive patients is valid, reliable, and feasible. The patients showed a willingness to continue with heartfulness meditation and yoga practices for participation in research for a longer duration. Further studies to confirm the tool’s efficacy should be conducted with a large sample size.Trial Registration:CTRI/2024/01/061035","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/9289232","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/9289232","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

The module was designed and developed at Heartfulness Institute, Kanha Shanti Vanam, Hyderabad. The Department of Medicine, MGM Medical College & Hospital, MGMIHS, Navi Mumbai, carried out the validation and subsequently pilot-tested on volunteers. Forty experts were selected to validate the contents of IAHFNM & YP which was designed after a thorough review of meditation and yoga literature. A total of 23 items were included, and each item was rated as essential or not essential by the experts, based on which the content validity ratio (CVR), Item-Level Content Validity Index (I-CVI), and Scale-Level Content Validity Index Average (S-CVI/Ave) were calculated. Reliability analysis and a pilot study for the feasibility of IAHFNM & YP for hypertensive patients were also done. All 23 practices exhibited significant CVR (≥ 0.29), I-CVI (> 0.79), and S-CVI/Ave (> 0.9); thus, the tool was found to have valid contents. Cronbach’s alpha value for the tool was 0.95 which was highly reliable. Feasibility analysis in hypertensive participants showed that the tool is reliable and implementable. The IAHFNM & YP tool designed for hypertensive patients is valid, reliable, and feasible. The patients showed a willingness to continue with heartfulness meditation and yoga practices for participation in research for a longer duration. Further studies to confirm the tool’s efficacy should be conducted with a large sample size.

Trial Registration:CTRI/2024/01/061035

Abstract Image

查看原文本刊更多论文

针对高血压参与者的 "心灵冥想与瑜伽综合疗法"（IAHFNM 与 YP）的设计、验证与可行性研究

该模块由海德拉巴 Kanha Shanti Vanam 的 Heartfulness 研究所设计和开发。纳维孟买 MGMIHS 的 MGM 医学院和医院医学系进行了验证，随后在志愿者中进行了试点测试。在对冥想和瑜伽文献进行全面审查后，设计了 IAHFNM & YP。共包括 23 个项目，每个项目均由专家评定为必要或非必要，并据此计算出内容效度比（CVR）、项目级内容效度指数（I-CVI）和量表级内容效度指数平均值（S-CVI/Ave）。此外，还进行了可靠性分析，并对高血压患者使用 IAHFNM & YP 的可行性进行了试点研究。所有 23 项实践均显示出显著的 CVR（≥ 0.29）、I-CVI（0.79）和 S-CVI/Ave（0.9），因此该工具的内容是有效的。该工具的 Cronbach's alpha 值为 0.95，具有高度可靠性。对高血压患者进行的可行性分析表明，该工具是可靠和可实施的。为高血压患者设计的 IAHFNM & YP 工具是有效、可靠和可行的。患者表示愿意继续进行心性冥想和瑜伽练习，以便更长时间地参与研究。为证实该工具的有效性，应进行大样本量的进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Therapeutics 医学-心血管系统

CiteScore

5.60

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.